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Introduction: The forkhead transcription factor FOXM1 coordinates expression of cell cycle–related genes and plays
a pivotal role in tumorigenesis and cancer progression. We previously showed that FOXM1 acts downstream of
14-3-3ζ signaling, the elevation of which correlates with a more aggressive tumor phenotype. However, the role
that FOXM1 might play in engendering resistance to endocrine treatments in estrogen receptor–positive (ER+)
patients when tumor FOXM1 is high has not been clearly defined yet.
Methods: We analyzed FOXM1 protein expression by immunohistochemistry in 501 ER-positive breast cancers.
We also mapped genome-wide FOXM1, extracellular signal-regulated kinase 2 and ERα binding events by chromatin
immunoprecipitation followed by high-throughput sequencing (ChIP-seq) in hormone-sensitive and resistant breast
cancer cells after tamoxifen treatment. These binding profiles were integrated with gene expression data derived
from cells before and after FOXM1 knockdown to highlight specific FOXM1 transcriptional networks. We also
modulated the levels of FOXM1 and newly discovered FOXM1-regulated genes and examined their impact on the
cancer stem-like cell population and on cell invasiveness and resistance to endocrine treatments.
Results: FOXM1 protein expression was high in 20% of the tumors, which correlated with significantly reduced
survival in these patients (P = 0.003 by logrank Mantel-Cox test). ChIP-seq analyses revealed that FOXM1 binding
sites were enriched at the transcription start site of genes involved in cell-cycle progression, maintenance of stem
cell properties, and invasion and metastasis, all of which are associated with a poor prognosis in ERα-positive
patients treated with tamoxifen. Integration of binding profiles with gene expression highlighted FOXM1 transcriptional
networks controlling cell proliferation, stem cell properties, invasion and metastasis. Increased expression of FOXM1 was
associated with an expansion of the cancer stem-like cell population and with increased cell invasiveness and resistance
to endocrine treatments. Use of a selective FOXM1 inhibitor proved very effective in restoring endocrine therapy
sensitivity and decreasing breast cancer aggressiveness.
Conclusions: Collectively, our findings uncover novel roles for FOXM1 and FOXM1-regulated genes in promoting
cancer stem-like cell properties and therapy resistance. They highlight the relevance of FOXM1 as a therapeutic target
to be considered for reducing invasiveness and enhancing breast cancer response to endocrine treatments.* Correspondence: katzenel@illinois.edu
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Endocrine resistance in breast cancer is a process that
appears to result from upregulation of growth factor and
protein kinase signaling pathways that provide an alter-
nate mechanism in support of tumor cell proliferation
and survival [1-4]. Tamoxifen (TAM) has proven to be
one of the most successful agents in the management of
estrogen receptor-positive (ER+) breast cancers. When
effective, it suppresses tumor growth and reduces the
risk of relapse. Unfortunately, with time, about 50% of
patients with ER+ breast cancer stop benefiting from
TAM treatment and acquire resistance, leading to disease
progression. Despite significant advances in defining some
of the factors involved [5-8], the mechanisms underlying
endocrine resistance are complex and not fully under-
stood. Therefore, we have been interested in identifying
and targeting, by inhibition or downregulation, key players
that mediate endocrine resistance in ER+ breast cancer.
Many cancers are maintained in a hierarchical
organization of rare cancer stem cells (CSCs) and more
plentiful differentiated tumor cells. CSCs that are resist-
ant to treatment not only have the capacity to give rise
to differentiated tumor cells but also can lead to recur-
rence, metastasis and disease progression [9-11]. There-
fore, endocrine resistance might be associated with the
outgrowth of CSCs by promoting expansion of the CSC
population or augmenting the production of key factors
that regulate the CSC phenotype.
In our previous studies, we reported a correlation be-
tween overexpression of the protein 14-3-3ζ and early on-
set of recurrence in breast cancer patients [12]. We also
uncovered a previously unknown relationship between 14-
3-3ζ and FOXM1 in TAM resistance in breast cancer, with
14-3-3ζ acting upstream of FOXM1 to enhance the ex-
pression of FOXM1-regulated genes [13].
FOXM1 is a forkhead transcription factor that binds to
chromatin and plays an important role in ERα signaling
pathways [14]. FOXM1 is a key regulator of the cell cycle
and is essential for formation of the mitotic spindle and
correct chromosome segregation [15]. Its expression is
very low in normal tissues, but elevated in many types of
cancers [16-18]. High expression of FOXM1 is associated
with a poor prognosis [19-22]. In addition to its role in mi-
tosis and cytokinesis, this transcription factor regulates
genes that control critical aspects of cancer, including dif-
ferentiation [23], angiogenesis [24] and metastasis [16,20].
In this study, we show that TAM-resistant (TamR) cells
contain higher levels of FOXM1 than do parental cells
sensitive to growth inhibition by TAM and that this is cor-
related with the presence of a larger CSC population. Fur-
ther, in large cohorts of patient breast tumors that we
examined, high FOXM1 RNA and protein levels were
found to correlate with a significantly faster onset of
tumor recurrence and reduced overall survival. In culturedcells, FOXM1 promoted breast cancer aggressiveness
and therapy resistance which could be reversed by
FOXM1 inhibition or knockdown. Our genome-wide
analyses using chromatin immunoprecipitation followed
by high-throughput sequencing (ChIP-seq) revealed
that TAM-specific FOXM1 binding sites are associated
with genes encoding markers of CSCs and invasiveness
and that overexpression of FOXM1 increases the pro-
portion of CSCs and directly regulates the production
of factors that promote aggressiveness and therapy re-
sistance in breast cancer.
Methods
Cell culture, small interfering RNA, overexpression and
ligand treatments
MCF-7 and T47D cells were obtained from the Ameri-
can Type Culture Collection (Manassas, VA, USA) and
TamR MCF-7 cells (TamR cells) described previously
[25] were cultured in minimal essential medium (MEM;
Sigma-Aldrich, St Louis, MO, USA) supplemented with
5% calf serum (HyClone Laboratories, Logan, UT, USA),
100 μg/ml penicillin-streptomycin (Invitrogen, Carlsbad,
CA, USA) and 25 μg/ml gentamicin (Invitrogen). Four
days before control vehicle or ligand treatment, cells were
seeded in phenol red-free MEM containing 5% charcoal-
dextran-treated calf serum. Medium was changed on days
2 and 4 of culture before treatment. For three-dimensional
cultures, 100 μl of Matrigel was spread in each well of a
12-well plate, and 8,000 cells were seeded and grown for 6
to 10 days. Spheroids were stained with Giemsa-Wright
stain for 15 minutes at room temperature and washed
twice with 1× phosphate-buffered saline (PBS) for 5 mi-
nutes each. Small interfering RNA (siRNA) experiments
were carried out by transfecting 50 nM of siCtrl, siFOXM1
or siABCG2 from DharmaFECT reagent (Dharmacon,
Lafayette, CO, USA) for 72 hours. Overexpression was
performed as previously reported [12].
ChIP and ChIP–reChIP assays
Cells were treated with 0.1% EtOH (vehicle) or 1 μM 4-
hydroxytamoxifen (4-OH-TAM) for 45 minutes after pre-
treatment for 1 hour with the FOXM1-selective alternate
reading frame (ARF) peptide inhibitor or mutant ARF
control peptide [26] or with extracellular signal-regulated
kinase kinase 1 (MEK1) inhibitor (AZD6244; Sellek
Chemical, Houston, TX, USA) or control vehicle. After
treatment, chromatin was cross-linked using 1% formalde-
hyde for 15 minutes at room temperature. Cells were
washed with PBS, harvested and sonicated three times for
10 seconds in ChIP lysis buffer. Lysates were centrifuged
for 10 minutes at 4°C. For immunoprecipitation of DNA–
protein complexes, lysates were incubated overnight with
antibodies to FOXM1 (GeneTex, Irvine, CA, USA) or
extracellular signal-regulated kinase 2 (ERK2; Santa Cruz
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washed three times with radioimmunoprecipitation assay
(RIPA) buffer (three times) and two times with Tris-EDTA
(ethylenediaminetetraacetic acid). Following the overnight
incubation at 65°C, ChIP DNA was isolated using a QIA-
GEN PCR purification kit (QIAGEN, Valencia, CA, USA)
as per the manufacturer’s suggestions. The DNA was used
for ChIP-seq analysis and quantitative real-time PCR.
Sequential chromatin immunoprecipitation (ChIP-
reChIP) experiments were done following the same ChIP
protocol. After the first pull-down, immunoprecipitated
material was recovered with 10 mM dithiothreitol in im-
munoprecipitation buffer at 37°C for 30 minutes, diluted
and subjected to a second round of immunoprecipita-
tion. Quantitative RT-PCR (qRT-PCR) was used to cal-
culate recruitment to the regions studied, as described
elsewhere [27].
ChIP-seq and clustering analysis
For characterization of the FOXM1 and ERK2 cistromes
from cells treated with 4-OH-TAM, the ChIP DNA was
prepared into libraries according to Illumina Solexa
ChIP-seq sample-processing methods (San Diego, CA,
USA), and single-read sequencing was performed using
the Illumina Solexa Genomic Analyzer using methods de-
tailed previously [28]. Sequences generated were mapped
uniquely onto the human genome (hg19) by Bowtie2 [29]
with the default settings. A model-based analysis of ChIP-
Seq algorithm [30] was used to identify enriched peak re-
gions (default settings) with a P-value cutoff of 6.0E-7 and
false discovery rate of 0.01. ChIP-seq data for FOXM1 and
ERK2 binding sites are given as BED files in Additional file
1: Table S1. Cistrome data for ERα in MCF-7 cells treated
with Tam are derived from a previous study [31].
The seqMINER density array method with a 300-bp
window in both directions was used for the generation
of clusters (that is, groups of loci having similar com-
positional features) [32]. This ChIP-seq data interpret-
ation platform allows the comparison and integration of
multiple ChIP-seq data sets and their extraction and
visualization of specific patterns as described previously
[28]. BED files for each cluster were used for further
analysis with Galaxy Cistrome integrative analysis tools
(Venn diagram, conservation, Cis-regulatory Element
Annotation System (CEAS)) [33].
Motif and Gene Ontology category analysis
Overrepresented Gene Ontology (GO) biological pro-
cesses were determined by utilizing the web-based DAVID
Bioinformatics Resources database [34,35], GeneSpring
and web-based GREAT (Genomic Regions Enrichment of
Annotations Tool) software [36]. Motif enrichment ana-
lysis was done using SeqPos [33]. Conservation of the
binding sites was determined using web-based CEASsoftware of the Cistrome/Galaxy platform [37]. Default pa-
rameters were used in all software.
RT-PCR and quantitative PCR
Total RNA was isolated from cells using TRIzol reagent
(Invitrogen). RNA samples were reverse-transcribed
using SuperScript II reverse transcriptase (Invitrogen),
and RT-PCR was carried out on the ABI Prism 7900HT
Sequence Detection System using SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA)
as described previously [38]. Primer sequences for the
genes studied were obtained from the Harvard Primer
Bank [39]. Sequences are available on their website.
Microarray gene expression data analysis and statistics
Total RNA was used to generate complementary RNA
(cRNA), which was labeled with biotin according to pro-
tocols recommended by Affymetrix (Santa Clara, CA,
USA). All analyses were done using three or more samples
for each treatment. The biotin-labeled cRNA was hybrid-
ized to Affymetrix U133 plus 2.0 GeneChips, which con-
tain oligonucleotide probe sets for over 47,000 transcripts.
After being washed, the chips were scanned and analyzed
using Affymetrix processing software. All microarray gene
expression data have been deposited in the Gene Expres-
sion Omnibus database [GEO:GSE55204]. CEL files were
processed using GeneSpring GX 11.0 software (Agilent
Technologies, Santa Clara, CA, USA) to obtain fold
changes and P-values with the Benjamini and Hochberg
multiple-test correction [40] for each gene for TAM treat-
ment relative to the vehicle control in each cell back-
ground. We considered genes with fold changes greater
than two and P-values <0.05 as statistically significant and
differentially expressed. For analyses of microarray data
sets from TAM- treated breast cancer patients, we used
Frasor et al. data [GEO:GSE1379] [38] and Buffa et al.
data [GEO:GSE2221] [41]. Multifactor analysis was com-
puted in WinSTAT statistics add-in for Excel software (R.
Fitch software). Differences between two groups were
assessed using an unpaired t-test. Data involving more
than two groups were assessed by analysis of variance with
Dunnett’s multiple-comparisons test. Differences were
considered significant at P < 0.05. Additional statistical
analyses done are indicated in the figure legends.
Western blot analysis
Whole-cell extracts were prepared using 1× RIPA lysis buf-
fer (Upstate/Chemicon, Billerica, MA, USA) supplemented
with 1× cOmplete Protease Inhibitor Cocktail mixture
(Roche Applied Science, Basel, Switzerland). Proteins were
separated on 4% to 20% gradient SDS-PAGE gels and
transferred to nitrocellulose membranes. For Western blot
analysis, we used antibodies against FOXM1, ERK1 and
ERK2 (Santa Cruz Biotechnology), β-actin (Sigma-Aldrich),
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(Cell Signaling Technology, Danvers, MA, USA) and CD44
(BD Biosciences, San Jose, CA, USA).
Cell proliferation assay
A WST-1 assay (Roche Applied Science) was used to
quantify cell viability. Absorbance was read at 450 nm
on a PerkinElmer Victor X Multilabel Plate Reader
(PerkinElmer, Waltham, MA, USA), and all assays were
performed in triplicate as described elsewhere [13,42].
Fluorescence-activated cell sorting and
immunofluorescence
For fluorescence-activated cell sorting (FACS), cells were
detached and then stained with antibodies for CD44,
CD24, ABCG2 (BD Biosciences and Cell Signaling Tech-
nology) at 1:100 dilution in PBS containing 1% fetal calf
serum. FACS-sorted cells were collected into cell medium
for plating or into RNAlater™ buffer for RNA extraction.
To test for ABCG2+ activity, 1 × 106 cells were incubated
with 5 μM Hoechst 33258 dye at 37°C for 90 minutes. All
samples were analyzed and sorted using a FACSAria III in-
strument (BD Biosciences).
Invasion assay
Breast cancer cells were seeded on precoated filters (8-μm
pore size) after membrane rehydration (BD Biosciences).
Following incubation for 48 hours at 37°C, cells were fixed
in 10% formalin buffer and stained using crystal violet.
Noninvasive cells on the surface of the filter were removed
using a cotton swab. Invasion was quantified by determin-
ing the percentage of cells that had invaded the filter com-
pared to the total number seeded as described previously
[13,42].
Breast tumor cohort and FOXM1 immunohistochemistry
and statistical analysis
A tissue microarray (TMA) from the Samsung Medical
Center Breast Cancer Biomarker Study was utilized for
the analysis of FOXM1 status. Detailed clinical features
and molecular subtype classification have been reported
elsewhere [43,44]. Briefly, from among 815 tumors, 501
were assigned as ERα-positive and used for the immuno-
histochemical detection of FOXM1 expression. TMA
sections were incubated for 1 hour at room temperature
with mouse anti-human FOXM1 antibody (ab55006;
Abcam, Cambridge, MA, USA) diluted 1:400. The detec-
tion system EnVision+ for mouse antibody (K4001; Dako,
Glostrup, Denmark) was applied according to the manufac-
turer’s instructions. Slides were stained with liquid diamino-
benzidine tetrahydrochloride (DAB+), a high-sensitivity
substrate chromogen system (K3468; Dako). Counterstain-
ing was performed with Mayer’s hematoxylin. FOXM1 ex-
pression was scored using a semiquantitative method basedon the following four classes: score 0 (no staining or nuclei
staining observed in <10% of the tumor cells), score 1+
(faint nuclear staining detectable in >10% of the tumor
cells), score 2+ (weak to moderate nuclear staining ob-
served in >10% of the tumor cells) and score 3+ (strong nu-
clear staining observed in >30% of the tumor cells).
Representative photomicrographs of each of the scoring
categories are shown in Additional file 2: Figure S4. Patients
with tumor scores ranging from 0 to 1 were classified as
FOXM1-negative/low expression, and those who had
scores of 2+ and 3+ were classified as FOXM1-high expres-
sion group. Disease-free survival was defined as the time
from the date of diagnosis to the date of documented re-
lapse, including locoregional recurrence and distant metas-
tasis. Survival curves were constructed using the Kaplan-
Meier method, and the logrank test was used to compare
the mean survival rates across the groups. The logrank test
with Bonferroni’s correction was used for the subgroup sur-
vival analysis.
Accession numbers and data availability
Gene expression data are available in the GEO database
[GEO:GSE55204]. ChIP-Seq data files for FOXM1 and
ERK2 binding sites in TAM-treated cells are given as
BED files in Additional file 1: Table S1.
Results
Estrogen receptor–positive breast tumors with high
expression of FOXM1 show early time to recurrence, and
tumors positive for both 14-3-3ζ and FOXM1 show earliest
time to recurrence
We reported previously that women with breast tumors
expressing high levels of the scaffold adaptor protein 14-
3-3ζ had a poor prognosis [12,13]. We also observed by
molecular analyses that FOXM1 was regulated by 14-3-3ζ
and was downstream of 14-3-3ζ [12]. Because FOXM1 is a
transcription factor that might regulate the expression of
genes that engender this less good patient outcome, we
first investigated the relationship between FOXM1 and
14-3-3ζ. As shown in Figure 1A, we examined the mRNA
expression of 27 forkhead transcription factors in 251 pri-
mary ERα-positive breast tumors. Notably, we observed
that expression of 14-3-3ζ in these tumors was most
highly correlated with expression of FOXM1 (r = 0.59, P =
9.03E-13) and next with FOXK2 expression (r = 0.38, P =
2.07E-10) (Figure 1A). This good correlation in expression
of FOXM1 and 14-3-3ζ/YWHAZ can be seen in the
gene expression heat map and in the factor analysis plot
(Figure 1A). Furthermore, tumors positive for both
14-3-3ζ and FOXM1 showed the earliest time to recur-
rence (P = 0.041) (Figure 1B). Of interest, analysis of our
microarray gene expression data from a large study with
TAM-treated breast cancer patients [38] showed that high
FOXM1 mRNA expression in tumors was associated with
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Figure 1 (See legend on next page.)
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Figure 1 Clinical data indicating that high expression of FOXM1 in estrogen receptor–positive breast tumors is correlated with
high expression of 14-3-3ζ and a poor clinical outcome. (A) Among the FOX family members, FOXM1 expression level most highly
correlated with 14-3-3ζ expression level in primary breast tumors. Microarray gene expression data are derived from our findings in 251
estrogen receptor–positive (ER+) breast tumors [38]. Box plots are shown for 27 FOX family members with error bars spanning minimum to
maximum values, and heat maps (below) show strong agreement between expression of FOXM1 and 14-3-3ζ/YWHAZ in breast tumors.
Factor analysis (top left) reveals that FOXM1 and 14-3-3ζ are linearly correlated. (B) Tumors positive for 14-3-3ζ and FOXM1 by IUC show
the earliest time to recurrence. P = 0.041 based on two-way analysis of variance with Dunnett’s multiple-comparisons test for multigroup
comparison. (C) Kaplan-Meier stratification of overall survival of tamoxifen-treated patients [38,41] based on FOXM1 mRNA expression.
(D) Kaplan-Meier analysis of disease-free survival of ER+ patients according to IHC scores for negative/low FOXM1 expression (blue curve)
versus high FOXM1 expression (green curve) (P = 0.003) analyzed using the logrank test.
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munohistochemistry (IHC) analysis of tumors from a co-
hort of 501 ERα-positive breast tumors revealed that high
expression of FOXM1 protein was associated with a much
poorer patient survival (Figure 1D). Kaplan-Meier logrank
survival analysis showed that time to recurrence was sig-
nificantly longer in patients with tumors negative or low
for FOXM1 compared to patients with tumors with high
FOXM1 protein (IHC score 2 or 3), which represented
about 20% of all ER+ tumors (P = 0.003) (Figure 1D).
FOXM1 multivariate Cox regression analysis also revealed
FOXM1 to have a significant P-value (P = 0.0048, odds ra-
tio = 1.661, 95% confidence interval = 1.177 to 2.343)
when FOXM1 was stratified by recurrence-free survival.
Thus, high FOXM1 mRNA or protein confers a worse
prognosis in ER+ breast cancers.
FOXM1 is elevated in tamoxifen-resistant breast cancer cells
and contributes to the endocrine-resistant phenotype
On the basis of these clinical observations, we examined
the levels of FOXM1 in MCF-7 parental and TamR cells
and found threefold higher levels of FOXM1 protein in
TamR cells (Figure 2A). We also monitored the kinetics
of increase of FOXM1 over time of 4-OH-TAM expos-
ure and observed a progressive and large (approximately
tenfold) increase in FOXM1 mRNA over the course of
100 weeks examined (Figure 2B). Moreover, proliferation
of control vehicle- or 4-OH-TAM treated cells was reduced
by FOXM1 siRNA (Figure 2C), which resulted in almost
full loss of FOXM1 protein. The TamR cells were growth-
stimulated by 4-OH-TAM (Figure 2C), and this stimulation
was eliminated, and cell proliferation decreased, when
FOXM1 was knocked down, indicating that FOXM1 plays
a role in the resistance to TAM (Figure 2C).
To assess how FOXM1 might affect gene regulation by
4-OH-TAM, we performed Affymetrix gene expression
microarray analysis on MCF-7 cells treated with 4-OH-
TAM with (siFOXM1) and without (siCtrl) knockdown of
FOXM1. Using a fold change greater than two and a P-
value <0.05, we found 546 genes to be differentially
expressed (Figure 2D). GO analysis of the functional anno-
tations of the differentially regulated genes revealed an en-
richment for cell cycle and chemotaxis categories in genesdownregulated upon knockdown of FOXM1 in 4-OH-
TAM-treated cells vs. control, whereas apoptosis and pro-
grammed cell death genes were upregulated and enriched
when FOXM1 was decreased by siFOXM1 treatment.
Genome-wide analysis of FOXM1 chromatin binding by
ChIP-seq, gene regulation by FOXM1 and clustering of
binding sites and delineation of gene functional categories
Next, we undertook the genome-wide characterization of
FOXM1 binding sites by ChIP-seq analysis to address how
TAM treatment affected the recruitment of FOXM1 to
specific genomic loci. In our FOXM1 cistrome from
MCF-7 cells treated with TAM, we observed that 22% of
the FOXM1 binding sites were also shared by ERα binding
sites after TAM treatment as reported by Hurtado et al.
[31] (Figure 2E). Hence, FOXM1 also bound to a signifi-
cant number of unique sites, suggesting that FOXM1
might uniquely control the transcription of specific sets of
genes in a manner independent from ERα or that ERα
might operate along with FOXM1 present at different sites
via looping together of different chromatin locations.
A prominent feature of acquired TAM resistance is the
hyperactivation of MAPK. In light of this and the fact that
we have previously shown ERK2 to be recruited to chroma-
tin by ERα after estradiol treatment of breast cancer cells
[45], we assessed the recruitment of ERK2 to chromatin
after 4-OH-TAM exposure of cells and the extent of overlap
of ERK2 binding with FOXM1 and ERα binding (Figure 2E).
ERK2 and FOXM1 co-occupied more sites (47% of ERK2
sites) than ERK2 and ERα (35% of ERK2 sites), suggesting
that FOXM1 becomes a major transcription factor driving
ERK2 to the chromatin in the presence of 4-OH-TAM.
To obtain a better picture of the chromatin binding
landscape of these factors, we utilized a clustering ap-
proach using seqMINER [32], which compares the pres-
ence of multiple factors at a given chromosomal location
within a 600-bp window and clusters together those bind-
ing sites that share a similar pattern of factor localization.
We have previously shown, through this type of cluster
analysis, that binding sites can be classified based on a
series of factor recruitments, enabling the highlighting of
commonalities in regulatory modes for modulated genes




















































































































































Figure 2 (See legend on next page.)
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Figure 2 FOXM1 is elevated by tamoxifen treatment and genome-wide analysis of FOXM1, ERK2 and ERα chromatin binding sites by
ChIP-seq after tamoxifen treatment, and gene expression profiling, and clustering analyses. (A) FOXM1 protein levels in MCF-7 and
tamoxifen-resistant (TamR) cells monitored by Western blot analysis. (B) mRNA levels of FOXM1 mRNA over time of 1 μM 4-hydroxytamoxifen
(OH-TAM) exposure. The fold change in FOXM1 gene expression in the presence of tamoxifen- over vehicle-treated cells was calculated using the
comparative threshold cycle method, with the ribosomal protein 36B4 mRNA used as an internal control. (C) Proliferation of TamR control cells (Ctrl)
and cells with FOXM1 knockdown (siFOXM1). OD, Optical density. Data are mean ± SEM. **P < 0.01. (D) Heat map representing the expression levels of
OH-Tam-regulated genes in Ctrl and siFOXM1 MCF-7 cells treated with control vehicle or OH-Tam. Heat map shows fold change for gene expression in
Tam-treated vs. vehicle-treated cells with or without siFOXM1. (E) Venn diagram showing overlap of FOXM1, extracellular signal-regulated kinase 2
(ERK2) and estrogen receptor α (ERα) chromatin binding sites in cells after 45 minutes of OH-Tam treatment and chromatin immunoprecipitation
followed by high-throughput sequencing (ChIP-seq) analysis. FOXM1-Tam and ERK2-Tam cistrome data are from this study; the ERα-Tam cistrome data
are derived from Hurtado et al. [31]. (F) Clustering of the binding sites for FOXM1, ERK2 and ERα after cell treatment with Tam using seqMINER software
based on co-occupancy of the different factors within a 600-bp window. (G) Conservation of clusters C1, C2, C3 and C4 binding sites among
vertebrates. (H) Genomic location of clusters C1 to C4 binding sites identified by using the web-based CEAS tool. UTR, Untranslated region.
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FOXM1, ERK2 and ERα and directionality of gene regula-
tion marked classes of genes that are part of the same
functional category, denoted as clusters C1 to C4 (Figure 2F).
We further characterized these clusters based on GO
enrichment, transcription factor prediction using SeqPos,
genomic distribution and binding site conservation amongTable 1 Enriched Gene Ontology functions, pathways and tra
FOXM1 binding site clustersa
Enriched GO functions and pathways
Cluster 1 • Cell-cycle G2-M
• Stem cell development
• Increased adenoma
• TGF-β, PDGF and HIF2α signaling pathwa
Cluster 2 • Genes regulated by ESR1
• Genes upregulated in the luminal B subty
Cluster 3 Subgroup A
• Genes associated with acquired endocrine




• Cell substrate adherens junction
• Cytoskeleton regulation and rearrangeme
• Neoplasm
• Response to hypoxia
Subgroup C
• Epithelial cell development
• p53 pathway
• HIF1α transcription factor network
Cluster 4 • Translation
• Mammary gland hyperplasia
• Abnormal apoptosis
• Abnormal mitotic index
aAP-1, Activator protein 1; ATF3, Activating transcription factor 3; CREB, cAMP respo
HIF, Hypoxia-inducible factor; PDGF, Platelet-derived growth factor; TFs, Transcriptiospecies using CEAS. Cluster 1 (C1) was represented by
binding sites occupied by FOXM1 and ERK2 and was
enriched in genes involved in stem cell development, cell-
cycle G2-M-related genes and transforming growth factor β,
platelet-derived growth factor and hypoxia-inducible factor
2α (HIF2α) signaling pathways (Table 1). FOXM1 and




ERα, FOXM1, CREB, ATF3
pe of breast cancer




FOXM1, GATA, Elk, AP-1, JunD
nse element-binding protein; ERα, Estrogen receptor α; GO, Gene Ontology;
n factors; TGF-β, Transforming growth factor β.
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servation among species (Figure 2G) and had a substantial
presence of binding sites at proximal promoter genomic lo-
cations (Figure 2H, red), with clusters C2 and C3 showing
the greatest proportion of binding sites at enhancer and
intronic regions.
Cluster C2 (Figure 2F) was represented by binding
sites containing ERα, FOXM1 and ERK2. Genes har-
boring these binding sites were classified as ERα-
regulated genes that belonged to the luminal B breast
cancer subtype (Table 1). These binding sites were
mainly localized at enhancers (Figure 2H) and were
enriched for ERα, FOXM1, CREB and ATF3 binding
motifs. Cluster C3 was also characterized by occupancy
by FOXM1 and ERα, but not ERK2, and was associated
with genes expressed in endocrine-resistant cells and
genes associated with cytoskeletal regulation, focal ad-
hesion, epithelial cell development, the p53 pathway
and the HIF1α network (Table 1). C4 binding sites
were mainly enriched in genes involved in translation,
mammary gland hyperplasia and abnormal apoptosis
and mitotic index (Table 1). FOXM1, GATA, Elk, acti-
vator protein 1 and JunD motifs were enriched at these
sites. In Additional file 2: Figure S1, we also present for
comparison the binding site clustering pattern we ob-
tained for ERα in MCF-7 cells after treatment with
control vehicle, TAM or estradiol (E2) to explore if
FOXM1 and ERα co-occupy chromatin sites in the
presence of E2; this divided C3 into three subgroupsFrasor et al. (n=67)A
B
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Figure 3 Expression of FOXM1-regulated genes in cluster C1 stratify br
clustering of the expression of FOXM1-regulated C1 genes in two indepen
et al. [41]. (B) Kaplan-Meier stratification of samples based on expression an(Additional file 2: Figure S1). This analysis suggests
that FOXM1 might act as a pioneering factor for ERα
binding in the presence of TAM and E2. The cluster
patterns indicate that FOXM1 has specific (C1 and C4)
and common binding sites with ERα (C2 and C3) and
highlight the ERα-dependent and -independent roles
of FOXM1 in the breast cancer phenotype.
We compared the FOXM1 binding sites from our
study done in cells treated with 10−6 M 4-OH-TAM with
those described in the only other report on FOXM1
binding sites in MCF-7 cells, from Sanders et al. [14]
(Additional file 2: Figure S2). In that study, these binding
sites were examined in fetal bovine serum with no added
hormone or hormone antagonist. Of the FOXM1 bind-
ing sites we identified in TAM-treated cells, 55% were
also found in the Sanders et al. study. Many FOXM1
chromatin binding sites differed, however, no doubt
reflecting the very different cell treatment conditions.
Cluster 1 genes can discriminate between patient breast
tumors with different clinical outcomes
Genes within 20 kb of binding sites belonging to cluster
C1 and whose expression was impacted by FOXM1
knockdown were used to generate a gene predictor that
was employed to interrogate two large, independent
data sets [38,41] of ERα-positive breast cancer patients
treated with TAM. Hierarchical clustering was used to
stratify patients according to the expression of this C1
gene signature. As shown in Figures 3A and 3B, the C1Buffa et al. (n=134)
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east cancer patients based on outcomes. (A) Heat map of hierarchical
dent cohorts of patients treated with tamoxifen. Frasor et al. [38], Buffa
d hierarchical clustering of C1 genes.
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http://breast-cancer-research.com/content/16/5/436signature very effectively stratified the patients based on
clinical outcome, indicating that FOXM1 regulatory
sites and associated target genes may play a pivotal role
in tumor progression and TAM resistance. Of interest,
this signature included the genes HSPB1, CHEK1 and
MYBL2/B-MYB, all of which have functions known to
be associated with a poor prognosis [46-48].
FOXM1 recruitment to C1 chromatin binding sites and
impact of FOXM1 and extracellular signal-regulated
kinase 2 inhibition
To investigate the relationship between FOXM1 and ERK2
at sites of cobinding in cluster C1, we examined the recruit-
ment of FOXM1 and ERK2 following the treatment of
MCF-7 cells with 4-OH-TAM or vehicle in cells treated or
not with a FOXM1-specific inhibitor (p19ARF 26–44 peptide)
[49] or with a MEK1 inhibitor (AZD6244). We performed
ChIP followed by qPCR for regions where both FOXM1 and
ERK2 were identified in four of these genes: SIRT1, MYBL2,
CHEK1 and ABCG2 (Figure 4A). By Western blot analysis,
we show the effect of ERK1 and ERK2 knockdown on the
levels of FOXM1 (Figure 4B) and the effect of FOXM1
inhibition by ARF on the levels of pMAPK (Figure 4C).
Inhibition of FOXM1 by ARF or inhibition of ERK2 ac-
tivation by MEK1 using a MEK1 inhibitor significantly
decreased the recruitment of FOXM1 after 4-OH-TAM
treatment to all four genes tested (Figure 4D). We also
performed ChIP for ERK2 target genes before and after
ARF treatment, and we observed a significant reduction
in the recruitment of ERK2 to target gene loci after
FOXM1 inhibitor treatment (Figure 4E). Moreover, the
results of ChIP-reChIP experiments (Figure 4F) indi-
cated that FOXM1 and ERK2 co-occupy the investigated
genomic loci. We also modulated FOXM1 downward by
inhibition (ARF) or by knockdown (siRNA) or upward by
overexpression, and then examined effects on the mRNA
levels (Figure 4G) of genes harboring these binding sites
within a 20-kb window and on FOXM1 protein levels
(Figure 4H). We observed that FOXM1 was crucial for
the expression of SIRT1, MYBL2, CHEK1 and ASCG2
(Figure 4G). In addition, MEK1 inhibitor AZD6244
blocked TAM stimulation of these FOXM1 target genes
(Figure 4I). These findings suggest that the binding of
both FOXM1 and ERK2 to these chromatin binding
sites is required for expression of these genes. Of note,
transient knockdown of ERK1 or ERK2 significantly
decreased the cellular level of FOXM1 and inhibition of
FOXM1 also decreased the level of pMAPK, suggesting
that they are part of an interdependent regulatory loop.
FOXM1 transcription program drives expansion of cancer
stem-like cells
GO analysis of the C1 cluster revealed enrichment for
stem cell-related genes such as ABCG2 and SIRT1 and forthe nuclear transcription factors NF-YA, NF-YB and
NF-YC. On the basis of our bioinformatics analyses, we
therefore hypothesized that the FOXM1 transcription
program might play a role in the expansion of the CSC
population and that this phenomenon might promote the
acquisition of endocrine resistance. To validate this
hypothesis, we first investigated the percentage of CSCs by
FACS using CD44 and CD24 markers in MCF-7 parental
cells, in siFOXM1 and in FOXM1-overexpressing MCF-7
cells, and in TamR cells. Interestingly, we observed that
TamR cells had a fivefold higher percentage of CSCs com-
pared to parental MCF-7 cells (Figure 5A). Furthermore,
cells overexpressing FOXM1 had a CSC enrichment of
about eightfold compared to parental cells (Figure 5A)
and increased levels of CD44 as shown by a FACS inten-
sity plot (Figure 5B) and by a Western blot (Figure 5C).
We also monitored the level of CD44 mRNA during the
development of endocrine resistance and observed that
CD44 mRNA increased with weeks of 4-OH-TAM expo-
sure (Figure 5D). Thus, elevated FOXM1 is associated
with increased expression of CSC markers.
Given recent reports describing ABCG2 as a marker
of CSCs [50-52], and on the basis of our gene expression
data, we compared the levels of ABCG2 in MCF-7 par-
ental and TamR cells after FACS separation and ob-
served a great enrichment (approximately 50-fold) in the
ABCG2+ population in the TamR cells (Figure 5E).
Moreover, ABCG2 mRNA levels increased progressively
over time with TAM exposure, with the level increasing
by about fivefold by 10 weeks and by approximately
twelvefold by 100 weeks (Figure 5F). Next, to evaluate the
functional role of FOXM1 in regulating the expression of
ABCG2 and its involvement in TAM resistance, we re-
duced the level of ABCG2 by siRNA-mediated knockdown
in TamR cells to 20% of the initial ABCG2 mRNA level
(Additional file 2: Figure S4) and then tested cell sensitivity
to 4-OH-TAM. As shown in Figure 5G, 4-OH-TAM stim-
ulated proliferation of the control TamR cells, whereas
cells rendered deficient in ABCG2 became sensitive to
growth suppression by 4-OH-TAM (Figure 5G).
Next, by FACS, we separated TamR cells based on the
ABCG2 expression marker (Figure 5H) and evaluated cell
proliferation in response to 4-OH-TAM in ABCG2+ and
ABCG2− cells, with or without FOXM1 knockdown.
Interestingly, 4-OH-TAM treatment in the control ABCG2+
cell population elicited growth stimulation, whereas FOXM1
knockdown in ABCG2+ cells prevented this growth-
stimulatory effect (Figure 5I). Thus, the ABCG2+ population
appears to contribute to the endocrine-resistant phenotype
(Figure 5I). Because the ABCG2+ and ABCG2− cell popula-
tions express ERα mRNA at levels similar to each other and
to those of the overall TamR cell population (Figure 5J),
changes in ERα level do not explain their differences in







Figure 4 (See legend on next page.)
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Figure 4 FOXM1 and ERK2 co-occupy genomic loci of cluster C1 genes, and impact of knockdown of FOXM1, or ERK1, or ERK2, or
treatment with FOXM1 inhibitor. (A) UCSC Browser location of the binding sites we identified for FOXM1, estrogen receptor α and extracellular
signal-regulated kinase 2 (ERK2) for four representative genes in the C1 cluster (SIRT1, B-Myb, CHEK1 and ABCG2). (B) Western blot showing ERK1,
ERK2 and FOXM1 levels after small interfering RNA (siRNA) knockdown of ERK1 or ERK2. (C) Western blot showing FOXM1 and phosphorylated
mitogen-activated protein kinase levels after alternate reading frame (ARF) (FOXM1 inhibitor) treatment. (D) FOXM1 recruitment to chromatin sites
was assessed after ARF or extracellular signal-regulated kinase kinase 1 (MEK1) inhibitor treatment and followed by quantitative RT-PCR (qRT-PCR).
(E) Chromatin immunoprecipitation (ChIP) for ERK2 was assessed after ARF or control vehicle treatment. (F) ChIP-reChIP showing binding site
co-occupancy by FOXM1 and ERK2. Immunoprecipitation was done first for FOXM1 and then for ERK2. (G) Levels of representative C1 genes in
siCtrl- or siFOXM1-treated cells or in cells with ARF treatment or overexpression of FOXM1. (H) Western blot showing FOXM1 levels after siRNA or
ARF treatment or overexpression. (I) MEK1 inhibitor blocks tamoxifen (TAM) stimulation of FOXM1 target genes. Cells were pretreated with 10 μM
MEK1 (AZD6244) or vehicle for 45 minutes and then treated with vehicle (0.1% EtOH) or 1 μM TAM in the presence or absence of inhibitor for 4
hours. RNA was isolated and qPCR analysis was done.
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sorted out ABCG2+ and ABCG2− TamR cells and cul-
tured the different populations for 12 days. Because one of
the defining characteristics of CSCs is their ability to
transport Hoechst dye, which is attributable to expression
of ABCG2, we examined Hoechst staining by FACS ana-
lysis. As shown in Figure 5K, ABCG2+ cells had a higher
percentage of side population (SP) Hoechst-negative cells
compared to the overall population of TamR cells or the
ABCG2− cells.
Soft agar and three-dimensional Matrigel spheroid for-
mation assays with the ABCG2+, ABCG2− and total
TamR cell populations revealed that ABCG2+ cells not
only had a more rapid growth rate compared to either
TamR or ABCG2− cells (Figure 5L) but also formed more
colonies (Figure 5M) and larger colonies (Figure 5N).FOXM1 overexpression increases breast cancer cell
aggressiveness and the expression of markers of
epithelial-to-mesenchymal transition and cytoskeletal
rearrangement
We observed a significant increase in the ABCG2+
population after overexpression of FOXM1 in MCF-7
cells for 72 hours, as examined by FACS (Figure 6A).
Through evaluation of the functional role of FOXM1 in
these cells by knockdown and overexpression, different
phenotypes were clearly observed in three-dimensional
Matrigel by as soon as 6 days (Figure 6B). No colony for-
mation was seen in the FOXM1-knockdown (siFOXM1)
population, whereas MCF-7 parental cells developed
dense, round colonies. Cells overexpressing FOXM1
showed a very distinct phenotype characterized by branch-
ing chains of cells and cellular protrusions indicative of a
migratory phenotype (Figure 6B). We also examined cell
invasiveness using Boyden chambers and confirmed that
FOXM1 overexpression engendered a more invasive
phenotype, whereas invasion was decreased by FOXM1
reduction (Figure 6C).
The invasion process is associated with increases in
EMT markers and loss of E-cadherin and requirescytoskeletal rearrangement. Hence, it was of interest that
altering the level of FOXM1 modulated EMT markers
SNAIL, TWIST, CXCR4 and E-cadherin (Figure 6D). Fur-
ther, our binding site cluster analysis revealed an enrich-
ment of FOXM1 and ERα co-occupancy on genes
involved in cytoskeleton regulation and rearrangement.
These include Rho-GTPase, CDC42 and RhoB. We
observed that the expression of these genes was critically
dependent on FOXM1 and was markedly altered by
changing the level of FOXM1 (Figure 6E). We made
similar observations in another ER+ cell line, T47D—
namely, an increase in TAM-regulated growth suppression
and a decrease in ABCG2, CDC42 and RhoB gene and
protein expression, as well as in pMAPK level, after
treatment of the cells with the FOXM1 inhibitor ARF
(Additional file 2: Figure S3).
As seen in Figure 6F, when we compared the levels of
FOXM1, CDC42 and RhoB in the sorted ABCG2+ and
ABCG2− populations and in the total TamR cells, we
consistently observed higher expression of FOXM1 and
Rho-GTPase genes in ABCG2+ cells (Figure 6F). Con-
sonant with this, ABCG2+ cells had higher invasion
capability compared to ABCG2− cells or the total TamR
population (Figure 5G). Hence, the subpopulation of
ABCG2+ cells within the overall TamR cell population is
responsible for the more invasive phenotype of the
TamR cells.Discussion
Our findings reveal that TAM resistance is associated
with upregulation of FOXM1 and with a FOXM1-
dependent gene expression program that enhances cell
proliferation and invasiveness and elicits an increase in
the proportion of CSCs within the breast cancer cell
population. These cells expressed many markers associ-
ated with stem cells and with decreased patient survival
[26], including CD44+ and CD24−/low markers, and
elevated EMT markers and properties. They also showed
high expression of ABC transporters that can result in
























































































































































































































































































































Figure 5 (See legend on next page.)
Bergamaschi et al. Breast Cancer Research 2014, 16:436 Page 13 of 18
http://breast-cancer-research.com/content/16/5/436
(See figure on previous page.)
Figure 5 FOXM1 increases expression of cancer stem cell markers and colony formation and invasiveness. (A) FOXM1 levels impact the
percentage of the CD44+/CD24−/low population in MCF-7 cells. CSC, Cancer stem cell-like cells; KD, Knockdown; OE, Overexpression; TamR,
Tamoxifen-resistant cells. (B) Increased levels of the marker CD44 by fluorescence-activated cell sorting (FACS) analysis. FACS analyses were done
in three separate experiments, and a representative profile from one FACS run is shown. Counts indicate number of events (that is, cells detected). Ctrl,
Control. (C) Western blot obtained after FOXM1 overexpression. (D) Expression of CD44 mRNA during exposure to Tamoxifen and the development of
TamR cells. (E) FACS profile of MCF-7 and TamR cells with ABCG2-gated population. FSC-H, Forward scatter height. (F) ABCG2 expression levels during
the time course of development of TamR cells. (G) Proliferation and 4-hydroxytamoxifen (OH-Tam) response with and without knockdown of ABCG2 in
TamR cells. OD, Optical density. (H) Schematic representation of the separation of ABCG2+ and ABCG2− populations in TamR cells. FITC, Fluorescein
isothiocyanate. (I) ABCG2+ and ABCG2− cell populations from TamR were sorted by FACS and monitored for proliferation in response to several
concentrations of OH-Tam with and without FOXM1 knockdown. (J) FACS analysis of estrogen receptor α (ERα) levels in ABCG2+ and
ABCG2− cell populations in TamR cells. (K) Percentage of Hoechst dye excluding side population (SP) cells in the overall TamR cell population or in
ABCG2+ and ABCG2− cells after 12 days of culture. (L) Image of soft agar assay and three-dimensional Matrigel spheroid formation in TamR, ABCG2+
and ABCG2− cells. (M) Number of colonies formed in the soft agar assay and (N) Diameter of the colonies from TamR cells or separated ABCG2+ and
ABCG2− cells. *P < 0.05; **P < 0.01.
Bergamaschi et al. Breast Cancer Research 2014, 16:436 Page 14 of 18
http://breast-cancer-research.com/content/16/5/436therapies due to drug efflux. These observations provide
guidance for how one might optimally combine agents tar-
geting specific characteristics of CSCs with conventional
treatments that reduce tumor bulk, thereby effecting long-
term benefits of ablating not only the overwhelming ma-
jority of the differentiated tumor cells but also removal of
the more endocrine-resistant CSCs that can result in re-
population of the tumor [53-56]. Indeed, inherent drug re-
sistance of CSCs is considered to be a crucial limitation to
treatment effectiveness [56].
We found that the CSCs represent only a small propor-
tion of the MCF-7 cell population, but that this fraction is
increased fivefold in TamR cells. Our observations uncover
a novel role for FOXM1 in inducing expansion of the CSC-
like population and in promoting an aggressive and
endocrine-resistant phenotype. These effects of FOXM1
likely underlie the strong association we have observed be-
tween high tumor FOXM1 and poor clinical outcome for
patients with ER+ breast cancers. Our examination of sev-
eral large data sets cumulatively representing about 1,000
ER+ breast tumors indicates that high FOXM1 expression
occurs in about 20% of ER+ breast cancers. Of note, the au-
thors of a recent report showed that FOXM1 and its regu-
lated target genes AURKA, AURKB and BIRC5/survivin
display the greatest prognostic discrimination among a
panel of genes analyzed for overall survival of patients with
ER+ breast cancer and an intermediate Oncotype DX 21-
gene recurrence score. High expression of these genes pre-
dicts a poorer outcome and suggests more aggressive selec-
tion of adjuvant chemotherapy for these patients [57].
As schematized in the model (Figure 6H), we show that
FOXM1 is elevated by TAM in a time-dependent manner
and that its expression is associated with markers of TAM
resistance. In previous studies, we identified the associ-
ation between FOXM1 and 14-3-3ζ, a protein also found
to be upregulated by TAM and elevated in TAM-resistant
tumors [13] via deregulation of miR-451 that targets 14-3-
3ζ [42] (Figure 6H). Our data now reveal that FOXM1, a
member of the family of forkhead transcription factors,fosters the enrichment of CSCs expressing stem cell
markers (for example, ABCG2, NF-YA, NF-YB and NF-
YC), mitosis-related genes and genes fostering invasive-
ness and motility (Rho-GTPases).
By ChIP-Seq and ChIP-reChIP, we show that TAM in-
duced recruitment of FOXM1 to the promoter regions
of cell-cycle mitosis-related genes and genes encoding
stem cell markers in MCF-7 and TamR cells, supporting
our hypothesis that FOXM1 promotes the expansion of
a highly proliferative CSC-like progenitor population
that is capable of self-renewal and can give rise to differ-
entiated progeny. We also observed FOXM1 upregula-
tion of EMT markers.
We focused much of this study on our novel finding of
the regulation by FOXM1 of stem cell–related genes that
were found by seqMINER analysis to be enriched in the C1
cluster. Moreover, this cluster was also enriched for targets
of miR-34a, recently reported to be important in regulating
the expression of self-renewal genes [58]. Interestingly, the
FOXM1 C1 cluster binding sites are co-occupied by ERK2,
suggesting a sophisticated mechanism by which FOXM1
and MAPK signaling may participate in the development of
endocrine resistance. Indeed, resistance to endocrine
therapies is known to be associated with enhanced sig-
naling through MAPK [1-3,5,8,45]. We show in this
study that the inhibition of MAPK activation with
MEK1 inhibitor, or alteration of FOXM1 expression by
the specific inhibitor ARF, impaired the recruitment of
these factors to chromatin, indicating that these two
factors control each other’s binding to C1 genomic re-
gions and that their copresence is essential for the ac-
tivation of transcription of C1 genes. Of note, it has
been shown that pMAPK induces phosphorylation of
FOXM1, enabling its translocation to the nucleus and
binding to genomic elements [59].
Further, our study reveals the interdependence of FOXM1
and MAPKs, with FOXM1 regulating the expression of
MAPK and FOXM1-knockdown decreasing the level of
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Figure 6 (See legend on next page.)
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Figure 6 FOXM1 increases expression of markers of epithelial-to-mesenchymal transition and invasiveness and induces an aggressive
phenotype in breast cancer cells. (A) Fluorescence-activated cell sorting (FACS) evaluation of the expression of ABCG2 in control (Ctrl) MCF-7 and
FOXM1-overexpressing (OE) MCF-7 cells. A FACS profile from one of three representative experiments is shown. FITC, Fluorescein isothiocyanate; FSC-H,
Forward scatter height. (B) Representative images obtained using a conventional inverted microscope show spheroids formed after modulation of the
levels of FOXM1. Higher-magnification section (inset) shows details of invadopodia advancing into the matrix. (C) Invasion assay in Ctrl, siFOXM1 and
FOXM1-OE MCF-7 cells after 48 hours. (D) Evaluation by quantitative RT-PCR (qRT-PCR) of the expression profiles of epithelial-to-mesenchymal transition
markers and (E) Rho-GTPase genes CDC42 and RhoB in Ctrl or siFOXM1- or FOXM1-OE MCF-7 cells. Mean ± SEM. *p < 0.05; **p < 0.01 vs. Ctrl.
(F) Evaluation by qRT-PCR of the expression profiles of FOXM1, CDC42 and RhoB in total TamR or ABCG2+ or ABCG2− cell populations. (G) Invasion
assay in TamR and in sorted ABCG2+ and ABCG2− cells. Data are mean ± SEM. *P < 0.05; **P < 0.01 vs. total TamR cells. (H) Schematic model depicting
our findings for the role of FOXM1 in engendering tamoxifen resistance, increased proliferation and invasion and the upregulation of stem cell markers,
Rho-GTPases and mitosis-related genes. ER, Estrogen receptor; MAPK, Mitogen-activated protein kinase.
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http://breast-cancer-research.com/content/16/5/436FOXM1 and MAPK are highly conserved among species,
which suggests an evolutionarily conserved function for these
genomic locations in different organisms. Moreover, our
bioinformatics analysis of cluster C1 FOXM1-regulated genes
was predictive of clinical outcome in women with TAM-
treated tumors. Among these genes, we found well-described
FOXM1 target genes such as B-Myb, c-Jun and c-Fos, as well
as important genes involved in stem cell maintenance.
Among the genes classified as CSC markers, we found multi-
drug resistance proteins (MDR1, ABCG5 and ABCG2), the
nuclear transcription factor NF-YA/B/C [60] and SIRT1 [61].
We concentrated in particular on studying the role of
FOXM1 in regulating the expression of ABCG2 because
ABCG2, also known as breast cancer resistance protein,
belongs to the ATP-binding cassette family. A defining
feature of CSCs is their ability to efflux Hoechst dye,
leading to the identification of the SP that is associated
with expression of the ABCG2 protein. Its expression
has been found in several stem cell tissues, including
lung and prostate cancer and glioblastoma [62,63].
Breast cancer SP cells have a high drug efflux capacity
owing to functional expression of ABC transporters such
as ABCG2. Although the mechanism by which multi-
drug resistance genes work in inducing chemotherapy
resistance has been described previously, a recent study
has implicated multidrug resistance proteins in hormone
resistance by showing that ABCG2 can efflux TAM [64].
These reports support what we observed upon knock-
down of either FOXM1 or ABCG2. With the reduction in
cellular FOXM1 or ABCG2, or by inhibition of FOXM1
using ARF peptide, we were able to restore growth sup-
pression by TAM to TamR cells, indicating that the levels
of ABCG2 impact treatment response and that the up-
regulation of ABCG2 by FOXM1 could provide an ex-
planation for the development of TAM therapy resistance.
In line with previous reports, our data show that our
ABCG2+ SP had higher invasiveness potential compared
to ABCG2− cells upon examination by three-dimensional
Matrigel culture and invasion assays. We further deter-
mined that this phenomenon is associated with their ele-
vated expression of CDC42 and RhoB genes, which harbor
FOXM1 binding sites co-occupied by ERα.Of note, we show that overexpression of FOXM1 in-
duced a cell phenotype characterized by branching, ex-
tended chains of cells and cellular protrusions distinctive
of a migratory phenotype and characterized by increased
expression of CDC42 and RhoB and higher invasiveness.
The GTP-binding proteins RhoB and CDC42 regulate
the organization and turnover of the cytoskeleton and
cell–matrix adhesions, which are a crucial feature in the
acquisition of an invasive phenotype and the development
of metastasis [65,66]. Further, in line with what has been
previously reported, our data confirm the binding of
FOXM1 to matrix metalloproteinases and VEGF [14] as
well as the regulation of EMT markers, thereby associating
FOXM1 at yet another level to the metastatic process [20].Conclusions
Collectively, our findings define FOXM1 as a master
regulator of Rho-GTPase and stem cell marker expression
and imply that reducing FOXM1 expression might be
effective in blocking tumor progression in several critical
ways: by decreasing the expression of mitosis-related genes,
by reducing invasion potential and by diminishing the pro-
portion of CSCs, thereby enhancing sensitivity to cancer
therapeutic agents. Indeed, the authors of several recent
reports have shown FOXM1 to be associated with resist-
ance to chemotherapeutic agents [67] and resistance to
radiation treatment [68].
Moreover, our functional work clearly shows that rende-
ring the FOXM1 pathway inactive by RNAi knockdown or
by use of the p19ARF 26–44 peptide [49], a selective
FOXM1 peptide inhibitor called ARF, was highly effective
in restoring endocrine sensitivity and suppressing breast
cancer aggressiveness. This ARF inhibitor has already been
shown to be effective in suppressing the development of
hepatocellular carcinoma in a preclinical model [69]. Taken
together, our findings have clinical implications for breast
cancer and potentially many other cancers where FOXM1/
pMAPK signaling pathways are active, and make a case for
the use of FOXM1 inhibitors in combination with current
therapies, including protein kinase inhibitors, to improve
effectiveness and long-term patient response to treatments.
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